Patents by Inventor Annamari Ranki
Annamari Ranki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10875916Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: GrantFiled: October 5, 2018Date of Patent: December 29, 2020Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno, Shimobi Onuoha
-
Publication number: 20190023779Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: ApplicationFiled: October 5, 2018Publication date: January 24, 2019Inventors: Adrian HAYDAY, Kai KROHN, Annamari RANKI, Part PETERSON, Kai KISAND, Edward STUART, Annalisa MACAGNO, Shimobi ONUOHA
-
Patent number: 10131709Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: GrantFiled: September 7, 2016Date of Patent: November 20, 2018Assignee: ImmunoQure AGInventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno, Shimobi Onuoha
-
Patent number: 9957319Abstract: Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.Type: GrantFiled: January 2, 2013Date of Patent: May 1, 2018Assignee: ImmunoQure AGInventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno
-
Patent number: 9725486Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: GrantFiled: January 13, 2014Date of Patent: August 8, 2017Assignee: Fit Biotech OYInventors: Kai Krohn, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20170051053Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: ApplicationFiled: September 7, 2016Publication date: February 23, 2017Inventors: Adrian HAYDAY, Kai KROHN, Annamari RANKI, Part PETERSON, Kai KISAND, Edward STUART, Annalisa MACAGNO, Shimobi ONUOHA
-
Patent number: 9475872Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: GrantFiled: January 2, 2013Date of Patent: October 25, 2016Assignee: ImmunoQure AGInventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
-
Publication number: 20160083798Abstract: A method of identifying and treating a subject having a tumor with down regulation of NAV3 (neuronal navigator 3) and with over expression of at least one gene product. The method may be used to identify a subject with a colorectal tumor, brain tumor or tumor of epidermal keratinocytes and selecting a treatment for a subject with a colorectal tumor, brain tumor or tumor of epidermal keratinocytes.Type: ApplicationFiled: June 2, 2015Publication date: March 24, 2016Applicant: VALIPHARMAInventors: Kai Krohn, Annamari Ranki, Emilia Carlsson, Kristian Ovaska, Valtteri Hayry, Sampsa Hautaniemi
-
Publication number: 20140363422Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: ApplicationFiled: January 2, 2013Publication date: December 11, 2014Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
-
Publication number: 20140335098Abstract: Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.Type: ApplicationFiled: January 2, 2013Publication date: November 13, 2014Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno
-
Publication number: 20140234361Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: ApplicationFiled: January 13, 2014Publication date: August 21, 2014Applicant: FIT Biotech OyInventors: Kai KROHN, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Patent number: 8143029Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products.Type: GrantFiled: December 21, 2006Date of Patent: March 27, 2012Assignee: ValipharmaInventors: Annamari Ranki, Sonja Hahtola, Leena Karenko, Soile Tuomela, Riitta Lahesmaa, Kai J. E Krohn
-
Publication number: 20120058108Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting tumors as well as methods for treating patients and predicting the prognosis to a patient. Specifically, the present invention relates to a method of demonstrating the malignant character of a tumor or cell subpopulation in a subject, to a method of predicting a prognosis, to a method of treating a subject having a tumor with NAV3 copy number change and with over expression of at least one gene or gene product selected from specific lists, and to a method of selecting a treatment to a subject. The present invention also relates to uses of NAV3 gene or gene product and at least one gene and/or gene product selected from specific lists for demonstrating the malignant character of a tumor or cell sub-population, for predicting a prognosis to a subject, for selecting a treatment to a subject, and for cancer therapy in a subject having a tumor with NAV3 copy number change.Type: ApplicationFiled: October 19, 2009Publication date: March 8, 2012Inventors: Kai Krohn, Annamari Ranki, Emilia Carlsson, Kristian Ovaska, Valtteri Häyry, Sampsa Hautaniemi
-
Patent number: 7803532Abstract: The present invention relates to novel methods for the diagnosis and therapy of lymphoproliferative diseases. Specifically, the present invention relates to novel methods for the diagnosis and therapy taking advantage of the detection of chromosomal breakpoints in chromosome 12 and/or translocation of chromosomal material from chromosome 12, said chromosomal breakpoints and/or translocation(s) being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL). The present invention further relates to the use of neuron navigator 3 gene (NAV3) or an equivalent or functional fragment thereof involved in chromosomal breakpoints in chromosome 12 and/or translocations thereof, said gene and/or translocations thereof being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL), as a diagnostic and therapeutic agent. The present invention also relates to the development of therapy.Type: GrantFiled: January 24, 2003Date of Patent: September 28, 2010Assignee: Helsingin Yliopiston RahastotInventors: Annamari Ranki, Leena Karenko, Marketta Kähkönen, Ritva Karhu, Tapio Visakorpi, Boguslaw Nedoszytko
-
Publication number: 20100143907Abstract: The present invention relates to the fields of genetics and oncology and provides methods for predicting and identifying tumors of epithelial origin. Specifically, the present invention relates to a novel method of predicting tumor initiation, tumor progression and/or carcinomas, the method comprising detecting genetic abnormality associated with tumors of epithelial origin. The present invention further relates to a novel method of identifying an individual with potential for developing carcinoma, the method comprising detection of genetic abnormalities. The present invention also relates to a method of predicting the progression of carcinomas and the transformation thereof to an aggressive variant, the method comprising detection of genetic abnormalities, which indicate the probability to develop carcinoma. The present invention also relates to a use of specific chromosomal region, a gene or a fragment thereof, and/or genetic markers for predicting tumor initiation, tumor progression and/or carcinoma.Type: ApplicationFiled: November 13, 2006Publication date: June 10, 2010Inventors: Kai Krohn, Wael Hassan, Päivi Peltomäki, Markku Helle, Sonja Hahtola, Annamari Ranki
-
Publication number: 20100035971Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products.Type: ApplicationFiled: December 21, 2006Publication date: February 11, 2010Inventors: Annamari Ranki, Sonja Hahtola, Leena Karenko, Soile Tuomela, Riitta Lahesmaa, Kai J.E. Krohn
-
Publication number: 20090252707Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: ApplicationFiled: January 27, 2009Publication date: October 8, 2009Applicant: FIT BIOTECH OYInventors: KAI KROHN, VESNA BLAZEVIC, MARJA TAHTINEN, MART USTAV, URVE TOOTS, ANDRES MANNIK, ANNAMARI RANKI, ENE USTAV
-
Patent number: 7510718Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing the vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of the vectors. The novel vectors comprise (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. The vectors lack a papilloma virus origin of replication.Type: GrantFiled: May 3, 2002Date of Patent: March 31, 2009Assignee: Fit Biotech Oyj PLCInventors: Kai Krohn, Vesna Blazevic, Marja Tahtinen, Mart Ustav, Urve Toots, Andres Mannik, Annamari Ranki, Ene Ustav
-
Patent number: 7498314Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising an expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component and a multimerized DNA sequence forming a binding site for the nuclear-anchoring protein, and optionally an expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest. The present invention further relates to DNA vaccines and gene therapeutics containing the novel vectors, to methods for the preparation of the novel vectors and the DNA vaccines and gene therapeutics.Type: GrantFiled: May 3, 2002Date of Patent: March 3, 2009Assignee: Fit Biotech Oyj PLCInventors: Kai Krohn, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20050221309Abstract: The present invention relates to novel methods for the diagnosis and therapy of lymphoproliferative diseases. Specifically, the present invention relates to novel methods for the diagnosis and therapy taking advantage of the detection of chromosomal breakpoints in chromosome 12 and/or translocation of chromosomal material from chromosome 12, said chromosomal breakpoints and/or translocation(s) being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL). The present invention further relates to the use of neuron navigator 3 gene (NAV3) or an equivalent or functional fragment thereof involved in chromosomal breakpoints in chromosome 12 and/or translocations thereof, said gene and/or translocations thereof being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL), as a diagnostic and therapeutic agent. The present invention also relates to the development of therapy.Type: ApplicationFiled: January 24, 2003Publication date: October 6, 2005Inventors: Annamari Ranki, Leena Karenko, Marketta Kahkonen, Ritva Karhu, Tapio Visakorpi, Boguslaw Nedoszytko